Retroperitoneal Sarcoma — Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma
Citation(s)
Baglan KL, Frazier RC, Yan D, Huang RR, Martinez AA, Robertson JM The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):176-83.
Harrison LB, Gutierrez E, Fischer JJ Retroperitoneal sarcomas: the Yale experience and a review of the literature. J Surg Oncol. 1986 Jul;32(3):159-64.
Letschert JG The prevention of radiation-induced small bowel complications. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1361-5. Review.
Lewis JJ, Brennan MF The management of retroperitoneal soft tissue sarcoma. Adv Surg. 1999;33:329-44.
Lewis JJ, Leung D, Woodruff JM, Brennan MF Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998 Sep;228(3):355-65. Review.
Robertson JM, Lockman D, Yan D, Wallace M The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):413-8.
Suit HD, Mankin HJ, Wood WC, Proppe KH Preoperative, intraoperative, and postoperative radiation in the treatment of primary soft tissue sarcoma. Cancer. 1985 Jun 1;55(11):2659-67.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
